A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics - Wikidata - wikimedia - TriplyDB

A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics

A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics

http://www.wikidata.org/entity/Q24602122

about

Personalized medicine and treatment approaches in hypertension: current perspectives Is personalized medicine achievable in obstetrics?Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate Drug-gene interactions: inherent variability in drug maintenance dose requirements Drug disposition and modelling before and after gastric bypass: immediate and controlled-release metoprolol formulations The burden and management of cytochrome P450 2D6 (CYP2D6)-mediated drug-drug interaction (DDI): co-medication of metoprolol and paroxetine or fluoxetine in the elderly.Cardiovascular Pharmacogenomics--Implications for Patients With CKD.Pharmacokinetics of selective β1-adrenergic blocking agents: prescribing implications.Drug safety and tolerability in prophylactic migraine treatment.Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments.Beta-blocker use and fall risk in older individuals: Original results from two studies with meta-analysis.Pharmacogenomics of heart failure: a systematic review.CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure.Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.Zero-order metoprolol pharmacokinetics after therapeutic doses: severe toxicity and cardiogenic shock.Potential utility of precision medicine for older adults with polypharmacy: a case series study.Heritability of metoprolol and torsemide pharmacokinetics.Pharmacokinetics of metoprolol during pregnancy and lactation.Phenotypic differences in nebivolol metabolism and bioavailability in healthy volunteers.An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy.Impact of CYP2D6 and ADRB1 polymorphisms on heart rate of post-PCI patients treated with metoprolol.

P2860

Q26751135-7F1F964F-E400-427D-9102-B9B5398B1C82 Q26864177-19918A7F-22D9-4244-9445-C99F44B0C916 Q33953368-B15E5C6C-A47E-417F-B57C-9A3BFA242F4B Q34154939-23D6917B-324C-4F8B-BA2F-D6A94ECBE455 Q36243622-C53D001C-45A5-4FD1-A410-FE18E472A395 Q36323469-84B33B70-669C-4692-9C08-570ADF75211E Q36696635-3EFC6464-5355-4F67-B292-6D3836A01BBC Q38226352-0F0AE3CA-A2BA-42DF-A0E8-BD37FF461783 Q38353242-0BE5BF2C-A865-4FAC-A271-E509CFC87154 Q38644870-A99DF50E-08D1-4D14-A404-91ECF2ACB802 Q38739070-AC34CE9F-905B-441A-BC38-7C05B69A38AE Q38998634-19607462-EF9C-4F10-A0CD-36CF0274BDFC Q39127810-5AD1EC4A-32DF-4319-8272-703AF8CAD0A7 Q39239760-E5A5C6A0-853D-4A7B-8280-EAE36FD8FFD6 Q39576196-5B31046D-29B7-411E-87DC-831AEBFC7B9B Q40655628-719DB69A-4420-492C-87BD-DF87D1339EB7 Q41398712-753ED38D-14B3-4061-BAB8-FD3C4D64A7DE Q41470697-084A7359-0600-4220-83F0-FF103D4E2D08 Q42731799-E0372669-52D0-4100-BA3B-E89B796DFA24 Q43423712-C867E070-8A8F-490D-97A5-E7A923F371BF Q47670477-FD9207DB-BA6C-47AE-BB06-4633862339F8

P2860

A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics

http://www.wikidata.org/entity/Q24602122

description

2013 nî lūn-bûn

@nan

2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics

@ast

A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics

@en

A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics

@nl

type

label

A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics

@ast

A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics

@en

A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics

@nl

prefLabel

A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics

@ast

A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics

@en

A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics

@nl

P1433

Q24602122-40D12AA1-4235-4232-BEAC-FA58D24ED334

P1476

Q24602122-BB081F40-687C-4F24-BCB5-797CC788A0E0

P2093

Q24602122-0D400137-6056-4CEC-A3E7-4AAA1E933AD2

Q24602122-25DE9C0B-5729-42A5-9237-9CBEA32B5BC5

Q24602122-25FD2F4B-714C-49A5-9BDC-7E15723BB400

Q24602122-4EBA7DF1-1577-474B-9531-E33A40F85071

P2860

Q24602122-0288D3C0-93A2-4C79-9013-8CF5A4BFACC7

Q24602122-046A735B-92D4-443C-9542-768E3DF9B956

Q24602122-077A76F5-E031-48D2-9F75-E1AEF2044483

Q24602122-151BDD03-29E6-4768-8F50-A279EEF54183

Q24602122-18E61F83-2E44-4955-B76F-A4EC9C16012B

Q24602122-1E921476-A436-4625-A118-75D7E0B11EF3

Q24602122-27635D9B-2184-46E0-81F7-00BC77BE2DDB

Q24602122-28938075-5903-4A93-930C-D0524F15B5BC

Q24602122-320928FE-B80E-4C53-8EB6-5B8E0A1BC2B3

Q24602122-3CEE2A4E-7826-4D4F-A7FE-2B2F8201DBDD

P304

Q24602122-B664EE03-A9D3-4AF4-85FB-737F428B7386

P31

Q24602122-1EA893D7-C8A6-4F30-9D68-D6C5F72725CD

Q24602122-975FF648-D805-4743-AC7F-38B294C16052

Q24602122-CF494744-746C-4A49-9BAB-97CEBB5361C7

P3181

Q24602122-BA077A93-1C2C-4BF3-8038-D7370DD94295

P356

Q24602122-170DAF4B-4E7A-45B9-874E-0E7F2F88A9AD

P407

Q24602122-F197CDFB-9E71-440F-AE88-C3EA1A1F959C

P433

Q24602122-26F1C2B5-114B-40FC-8607-D3FC8C7967D4

P478

Q24602122-CE7DB4AA-0CA2-47C0-A2AC-64C49029FC97

P577

Q24602122-07BF394B-14BE-4EB2-A990-BE09D5B59DF7

Q24602122-D0455129-D06B-451C-860F-991051E81638

P5875

Q24602122-C0F76837-27F1-43AA-9230-E79D3ED2525D

P698

Q24602122-05E896BE-3148-4678-948C-8FEEF008E8EA

P921

Q24602122-057814CE-0399-4C48-AC9C-3A7EAC21DA21

Q24602122-1C4529C5-7560-4BA5-81D9-80BB0A7E6846

Q24602122-3D39506C-EEC7-4D53-B291-42603ADEE0B9

Q24602122-45F4CF6F-77E5-48FD-A6C1-D383D067855D

Q24602122-7C4C7554-A55C-4F1A-8A77-BA838FDB2524

Q24602122-B6252320-981A-4531-A869-B1F5F8996377

Q24602122-B9E620C6-CE04-4388-B14B-47B33FE1C26F

Q24602122-BB98BEC4-FEAF-4F63-8189-5AD8CD01037D

P932

Q24602122-8C654A67-6169-4C91-A976-1FC3C43827E6

P3181

P356

P1433

Clinical Pharmacology & Therapeutics

P1476

A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics

@en

P2093

C M Blake

http://www.w3.org/2001/XMLSchema#string

E D Kharasch

http://www.w3.org/2001/XMLSchema#string

M Schwab

http://www.w3.org/2001/XMLSchema#string

P Nagele

http://www.w3.org/2001/XMLSchema#string

P2860

From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Pharmacogenetics, drug-metabolizing enzymes, and clinical practice

Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity.

Pharmacogenetics: from bench to byte--an update of guidelines.

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.

Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.

Genetic variation, β-blockers, and perioperative myocardial infarction.

Influence of hydroxychloroquine on the bioavailability of oral metoprolol

Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia.

P304

394-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2278002

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/CLPT.2013.96

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236691704

http://www.w3.org/2001/XMLSchema#string

P698

23665868

http://www.w3.org/2001/XMLSchema#string

P921

pharmacokinetics

mechanism of action

P932

3818912

http://www.w3.org/2001/XMLSchema#string